Article
Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood.
Institute of Psychiatry, King's Health Partners Centre for Neurodegeneration Research, King's College London, London, UK.
Journal of Alzheimer's disease: JAD (impact factor:
3.74).
03/2012;
30(3):685-710.
DOI:10.3233/JAD-2012-111592
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Plasma Based Markers of [(11)C] PiB-PET Brain Amyloid Burden.
[show abstract] [hide abstract]
ABSTRACT: Changes in brain amyloid burden have been shown to relate to Alzheimer's disease pathology, and are believed to precede the development of cognitive decline. There is thus a need for inexpensive and non-invasive screening methods that are able to accurately estimate brain amyloid burden as a marker of Alzheimer's disease. One potential method would involve using demographic information and measurements on plasma samples to establish biomarkers of brain amyloid burden; in this study data from the Alzheimer's Disease Neuroimaging Initiative was used to explore this possibility. Sixteen of the analytes on the Rules Based Medicine Human Discovery Multi-Analyte Profile 1.0 panel were found to associate with [(11)C]-PiB PET measurements. Some of these markers of brain amyloid burden were also found to associate with other AD related phenotypes. Thirteen of these markers of brain amyloid burden - c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolipoprotein E and immunoglobulin E - were used along with co-variates in multiple linear regression, and were shown by cross-validation to explain >30% of the variance of brain amyloid burden. When a threshold was used to classify subjects as PiB positive, the regression model was found to predict actual PiB positive individuals with a sensitivity of 0.918 and a specificity of 0.545. The number of APOE ϵ 4 alleles and plasma apolipoprotein E level were found to contribute most to this model, and the relationship between these variables and brain amyloid burden was explored.PLoS ONE 01/2012; 7(9):e44260. · 4.09 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
AD brain
AD diagnosis
AD subjects
Alzheimer's disease
blood gene expression alterations
brain changes
core mitochondrial ribosome complex
expression changes
functional response
leukocyte activation
mild cognitive changes
mild cognitive impairment
mirrors changes
monitoring future therapeutic interventions
peripheral leukocyte response
peripheral response
potential targets
relevant disease biomarkers
respiratory complex I-V genes
therapeutic approaches